Wall Street Zen Upgrades Rocket One Inc. Common Stock (NASDAQ:RKTO) to Sell

Rocket One Inc. Common Stock (NASDAQ:RKTO) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Sunday, Wall Street Zen reports.

Separately, Weiss Ratings downgraded Rocket One Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, October 14th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $5.00.

Rocket One Inc. Common Stock Price Performance

NASDAQ RKTO opened at $0.51 on Friday. The company’s 50-day simple moving average is $0.68 and its 200 day simple moving average is $0.86. Rocket One Inc. Common Stock has a twelve month low of $0.48 and a twelve month high of $2.45.

Rocket One Inc. Common Stock (NASDAQ:RKTO) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.19) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Rocket One Inc. Common Stock stock. Lido Advisors LLC grew its position in Rocket One Inc. Common Stock (NASDAQ:RKTO) by 100.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 39,000 shares of the company’s stock after purchasing an additional 19,500 shares during the period. Lido Advisors LLC owned about 0.20% of Rocket One Inc. Common Stock worth $33,000 as of its most recent filing with the SEC. 7.08% of the stock is currently owned by institutional investors and hedge funds.

Rocket One Inc. Common Stock Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.